[go: up one dir, main page]

PA8800401A1 - Productos quimioterapeuticos cristalinos - Google Patents

Productos quimioterapeuticos cristalinos

Info

Publication number
PA8800401A1
PA8800401A1 PA20088800401A PA8800401A PA8800401A1 PA 8800401 A1 PA8800401 A1 PA 8800401A1 PA 20088800401 A PA20088800401 A PA 20088800401A PA 8800401 A PA8800401 A PA 8800401A PA 8800401 A1 PA8800401 A1 PA 8800401A1
Authority
PA
Panama
Prior art keywords
crystal
chemotherapeutic products
chemotherapeutic
products
same
Prior art date
Application number
PA20088800401A
Other languages
English (en)
Inventor
B Borchardt Thomas
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PA8800401A1 publication Critical patent/PA8800401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA CRISTALINA 2 DESOLVATADA DE N-[4-[3-AMINO-1H-INDAZOL-4-IL]FENIL]-N-[2-FLUORO-5-METILFENIL]UREA, MANERAS PARA ELABORARLA, FORMULACIONES QUE COMPRENDEN A LA MISMA Y ELABORADAS CON LA MISMA Y METODOS DE TRATAMIENTOS DE PACIENTES QUE PADECEN UNA ENFERMEDAD PARA USARLA.
PA20088800401A 2007-10-19 2008-10-17 Productos quimioterapeuticos cristalinos PA8800401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98126507P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PA8800401A1 true PA8800401A1 (es) 2009-05-15

Family

ID=40174735

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088800401A PA8800401A1 (es) 2007-10-19 2008-10-17 Productos quimioterapeuticos cristalinos

Country Status (19)

Country Link
US (1) US7772404B2 (es)
EP (1) EP2195299A1 (es)
JP (1) JP2011500708A (es)
KR (1) KR20100084665A (es)
CN (1) CN101827825B (es)
AU (1) AU2008312534A1 (es)
BR (1) BRPI0818337A2 (es)
CA (1) CA2699356A1 (es)
CO (1) CO6270221A2 (es)
CR (1) CR11444A (es)
DO (1) DOP2010000111A (es)
EC (1) ECSP10010175A (es)
GT (1) GT201000099A (es)
MX (1) MX2010004287A (es)
PA (1) PA8800401A1 (es)
RU (1) RU2010119920A (es)
UA (1) UA99490C2 (es)
WO (1) WO2009052231A1 (es)
ZA (1) ZA201002094B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011329656B2 (en) 2010-11-19 2017-01-05 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN107106551A (zh) 2014-08-08 2017-08-29 弗赛特影像4股份有限公司 受体酪氨酸激酶抑制剂的稳定且可溶的制剂和其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638941B1 (en) * 2003-05-22 2010-06-02 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (en) * 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20100143459A1 (en) * 2006-11-09 2010-06-10 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
EP2195299A1 (en) 2010-06-16
CN101827825B (zh) 2012-11-21
BRPI0818337A2 (pt) 2017-05-23
CO6270221A2 (es) 2011-04-20
US20090124816A1 (en) 2009-05-14
US7772404B2 (en) 2010-08-10
CR11444A (es) 2010-10-05
AU2008312534A1 (en) 2009-04-23
ZA201002094B (en) 2011-11-30
MX2010004287A (es) 2010-04-30
UA99490C2 (en) 2012-08-27
KR20100084665A (ko) 2010-07-27
WO2009052231A1 (en) 2009-04-23
RU2010119920A (ru) 2011-11-27
DOP2010000111A (es) 2010-07-15
JP2011500708A (ja) 2011-01-06
GT201000099A (es) 2012-03-26
CN101827825A (zh) 2010-09-08
ECSP10010175A (es) 2010-06-29
CA2699356A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
CY1115180T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
HN2005000722A (es) Forma termodinamicamente estable de una sal tosilato
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
BRPI0517948A (pt) método para reduzir fosfato de soro em um paciente com necessidade do mesmo e unidade de dosagem oral
EA200801138A1 (ru) Применение флибансерина для лечения расстройств полового влечения в предклимактерический период
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
PA8800401A1 (es) Productos quimioterapeuticos cristalinos
PA8800601A1 (es) Productos quimioterapeuticos cristalinos
AR062784A1 (es) Tratmiento de los vertigos con acetil -l- leucina
ECSP077843A (es) Tratamiento o prevención del prurito
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
AR038698A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
DOP2010000113A (es) Productos quimioterapeuticos cristalinos
UY31407A1 (es) "productos quimioterapéuticos cristalinos"
CR11386A (es) Productos quimioterapeuticos cristalinos
CL2008002465A1 (es) Composición farmacéutica anhidra tópica, que comprende derivados de niacina y un portador aceptable, su aplicacón permite un bienestar sexual mejorado.
AR066108A1 (es) Utilizacion de 4- ciclopropilmetoxi -n- (3,5- dicloro-1 oxido- piridin- 4-il) -5-(metoxi) piridin-2- carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
SV2006002017A (es) Piperazinas derivadas de urea
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido
CL2008003551A1 (es) Uso de fosfato y fumarato de propionato de 3-(2,2,2-trimetilhidrazinio) en la preparacion de medicamentos utiles en la profilaxis y el tratamiento de aterosclerosis.